SRR1797243
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 50
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.350
- DNA_REPAIR+0.340
- E2F_TARGETS+0.320
- MYC_TARGETS_V2+0.290
- MYC_TARGETS_V1+0.240
- UNFOLDED_PROTEIN_RESPONSE+0.210
- G2M_CHECKPOINT+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
- PROTEIN_SECRETION+0.180
- PEROXISOME+0.150
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.550
- IL6_JAK_STAT3_SIGNALING-0.550
- ALLOGRAFT_REJECTION-0.510
- COAGULATION-0.480
- INFLAMMATORY_RESPONSE-0.480
- INTERFERON_GAMMA_RESPONSE-0.450
- ANGIOGENESIS-0.440
- INTERFERON_ALPHA_RESPONSE-0.440
- TNFA_SIGNALING_VIA_NFKB-0.440
- COMPLEMENT-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_VA5T4KAA | medulloblastoma | — | 0.947 |
| 2 | BS_NKEAAFMW | medulloblastoma | — | 0.934 |
| 3 | BS_KVNGNETA | medulloblastoma | — | 0.928 |
| 4 | BS_VJ2S5DVS | Ependymoma NOS | — | 0.928 |
| 5 | TCGA-E7-A5KE-01A-11R-A28M-07 | — | — | 0.926 |
| 6 | C3L-00993 | — | cohortSQ1 | 0.926 |
| 7 | BS_JFB984RG | medulloblastoma | — | 0.922 |
| 8 | TCGA-22-A5C4-01A-12R-A27Q-07 | — | cohortSQ1 | 0.920 |
| 9 | TCGA-AN-A04D-01A-21R-A034-07 | — | E | 0.920 |
| 10 | BS_9NJHQE9F | medulloblastoma | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |